Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Down 6.5% Following Weak Earnings

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)’s stock price fell 6.5% during trading on Friday following a dissappointing earnings announcement. The stock traded as low as $15.12 and last traded at $14.9750. 286,811 shares were traded during trading, a decline of 93% from the average session volume of 3,917,681 shares. The stock had previously closed at $16.01.

The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).

Key Corvus Pharmaceuticals News

Here are the key news stories impacting Corvus Pharmaceuticals this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $33 (from $32), implying substantial upside from current levels — a clear analyst vote of confidence that can support longer‑term buying interest. Oppenheimer Rating/Price Target
• Positive Sentiment: Company announced positive safety and efficacy data from cohort 4 of soquelitinib in a Phase 1 atopic dermatitis trial, including responses in patients with prior systemic therapy — this clinical progress materially de‑risks the program and supports future value for the pipeline. Atopic Dermatitis Trial Data
• Neutral Sentiment: Corvus released its Q4 2025 results and held an earnings call; management highlighted strategic advances tied to the pipeline and provided a business update, but the call materials are a mixed read for near‑term revenue prospects. Earnings Call Highlights
• Negative Sentiment: Q4 EPS came in at ($0.15), missing consensus by $0.01 — a small miss but enough to pressure sentiment in the absence of immediate revenue drivers; this likely contributed to the intraday pullback. Earnings Miss / Transcript
• Neutral Sentiment: Reported short‑interest updates in recent days show anomalous/zero values and appear unreliable — there is no clear evidence of a near‑term short squeeze or meaningful short pressure based on the published figures. (No actionable link available.)

Analysts Set New Price Targets

CRVS has been the subject of a number of recent analyst reports. Barclays raised their price objective on Corvus Pharmaceuticals from $16.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. HC Wainwright increased their target price on shares of Corvus Pharmaceuticals from $11.00 to $27.00 and gave the stock a “buy” rating in a research note on Tuesday, January 20th. Oppenheimer reiterated an “outperform” rating and set a $33.00 price target (up from $32.00) on shares of Corvus Pharmaceuticals in a research report on Friday. Mizuho set a $30.00 price target on shares of Corvus Pharmaceuticals in a research note on Thursday, January 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Corvus Pharmaceuticals in a research report on Friday. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Hedge Funds Weigh In On Corvus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Invesco Ltd. grew its position in shares of Corvus Pharmaceuticals by 12.7% during the fourth quarter. Invesco Ltd. now owns 43,583 shares of the company’s stock worth $336,000 after buying an additional 4,910 shares in the last quarter. Virtus Investment Advisers LLC raised its holdings in Corvus Pharmaceuticals by 18.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 31,783 shares of the company’s stock valued at $245,000 after acquiring an additional 4,946 shares in the last quarter. Wellington Management Group LLP lifted its stake in Corvus Pharmaceuticals by 74.7% in the fourth quarter. Wellington Management Group LLP now owns 314,683 shares of the company’s stock worth $2,423,000 after acquiring an additional 134,508 shares during the last quarter. Millennium Management LLC purchased a new position in Corvus Pharmaceuticals in the fourth quarter worth approximately $5,304,000. Finally, Logos Global Management LP acquired a new position in Corvus Pharmaceuticals during the 4th quarter worth approximately $3,850,000. Hedge funds and other institutional investors own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Performance

The stock’s 50-day simple moving average is $16.46 and its 200 day simple moving average is $10.53. The company has a market capitalization of $1.28 billion, a PE ratio of -30.64 and a beta of 0.78.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company’s research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.

Corvus’s lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.